Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABP 654 versus ustekinumab in moderate to severe plaque psoriasis
2020-003184-25Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab biosimilar ABP 654 in plaque psoriasis (2 arms), sponsored by Amgen. Started Oct 2020; status: completed.
02
Drugs
ustekinumab biosimilar ABP 654
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-003184-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003184-25.